These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 33008795)

  • 1. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving landscape of tissue-agnostic therapies in precision oncology.
    Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
    CA Cancer J Clin; 2024; 74(5):433-452. PubMed ID: 38814103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design.
    Fountzilas E; Tsimberidou AM; Hiep Vo H; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102703. PubMed ID: 38484408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision oncology: current and future platforms for treatment selection.
    Tang X; Berger MF; Solit DB
    Trends Cancer; 2024 Sep; 10(9):781-791. PubMed ID: 39030146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
    Thein KZ; Lemery SJ; Kummar S
    Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
    Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
    Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
    [No Abstract]   [Full Text] [Related]  

  • 19. Histology-agnostic drug development - considering issues beyond the tissue.
    Pestana RC; Sen S; Hobbs BP; Hong DS
    Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.